Logo image of CYCN

CYCLERION THERAPEUTICS INC (CYCN) Stock Fundamental Analysis

USA - NASDAQ:CYCN - US23255M2044 - Common Stock

2.39 USD
-0.11 (-4.4%)
Last: 10/6/2025, 9:34:45 PM
2.45 USD
+0.06 (+2.51%)
After Hours: 10/6/2025, 9:34:45 PM
Fundamental Rating

2

Taking everything into account, CYCN scores 2 out of 10 in our fundamental rating. CYCN was compared to 536 industry peers in the Biotechnology industry. CYCN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYCN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CYCN had negative earnings in the past year.
CYCN had a negative operating cash flow in the past year.
CYCN had negative earnings in each of the past 5 years.
In the past 5 years CYCN always reported negative operating cash flow.
CYCN Yearly Net Income VS EBIT VS OCF VS FCFCYCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -20.77%, CYCN is in the better half of the industry, outperforming 76.12% of the companies in the same industry.
Looking at the Return On Equity, with a value of -22.71%, CYCN belongs to the top of the industry, outperforming 83.21% of the companies in the same industry.
Industry RankSector Rank
ROA -20.77%
ROE -22.71%
ROIC N/A
ROA(3y)-104.94%
ROA(5y)-93.87%
ROE(3y)-166.99%
ROE(5y)-147.78%
ROIC(3y)N/A
ROIC(5y)N/A
CYCN Yearly ROA, ROE, ROICCYCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYCN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCN Yearly Profit, Operating, Gross MarginsCYCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for CYCN has been increased compared to 1 year ago.
The number of shares outstanding for CYCN has been increased compared to 5 years ago.
There is no outstanding debt for CYCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYCN Yearly Shares OutstandingCYCN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
CYCN Yearly Total Debt VS Total AssetsCYCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

CYCN has an Altman-Z score of -34.64. This is a bad value and indicates that CYCN is not financially healthy and even has some risk of bankruptcy.
CYCN has a Altman-Z score of -34.64. This is amonst the worse of the industry: CYCN underperforms 91.04% of its industry peers.
There is no outstanding debt for CYCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.64
ROIC/WACCN/A
WACCN/A
CYCN Yearly LT Debt VS Equity VS FCFCYCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

CYCN has a Current Ratio of 5.02. This indicates that CYCN is financially healthy and has no problem in meeting its short term obligations.
CYCN has a Current ratio of 5.02. This is comparable to the rest of the industry: CYCN outperforms 55.22% of its industry peers.
A Quick Ratio of 5.02 indicates that CYCN has no problem at all paying its short term obligations.
The Quick ratio of CYCN (5.02) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.02
Quick Ratio 5.02
CYCN Yearly Current Assets VS Current LiabilitesCYCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

CYCN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.04%, which is quite impressive.
The Revenue for CYCN have been decreasing by -15.01% on average. This is quite bad
EPS 1Y (TTM)46.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.97%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.23%
Revenue growth 5Y-15.01%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYCN Yearly Revenue VS EstimatesCYCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 1M 2M 3M 4M
CYCN Yearly EPS VS EstimatesCYCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYCN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCN Price Earnings VS Forward Price EarningsCYCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCN Per share dataCYCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CYCN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYCLERION THERAPEUTICS INC

NASDAQ:CYCN (10/6/2025, 9:34:45 PM)

After market: 2.45 +0.06 (+2.51%)

2.39

-0.11 (-4.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-12 2025-11-12
Inst Owners11.43%
Inst Owner Change0%
Ins Owners22.05%
Ins Owner Change0%
Market Cap7.98M
Analysts82.86
Price TargetN/A
Short Float %0.78%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.67
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.65
BVpS2.57
TBVpS2.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.77%
ROE -22.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-104.94%
ROA(5y)-93.87%
ROE(3y)-166.99%
ROE(5y)-147.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.02
Quick Ratio 5.02
Altman-Z -34.64
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.97%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.23%
Revenue growth 5Y-15.01%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y62.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y90.49%
OCF growth 3YN/A
OCF growth 5YN/A